Floatz logo

Spartalizumab

Cervical Squamous Cell Cancer

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Cervical Squamous Cell Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
Veliparib
National Cancer Institute (NCI)
Phase 2B
Rigosertib
Traws Pharma, Inc.
Phase 2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B

View all 32 →

Same molecule, other indications

Spartalizumab is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →